Walleye Trading’s Cyclerion Therapeutics CYCN Stock Holding History

Walleye Trading’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-500	Closed	-$28K	–	5215
2021 Q1	$28K	Buy	+500	New	+$37.6K	﹤0.01%	4475

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Trading's CYCN Position: Q2 2021 in Review

Walleye Trading sold out of Cyclerion Therapeutics (CYCN) in Q2 2021, closing a stake of 500 shares — an estimated $28K sold.

Walleye Trading first reported a position in CYCN in Q1 2021 and held it in 1 quarter. The position peaked at $28K in Q1 2021. 67 funds tracked by Wall St. Rank hold CYCN as of Q2 2021.

Walleye Trading reported no remaining Cyclerion Therapeutics position as of Q2 2021 after selling out during the quarter.
Walleye Trading sold 500 Cyclerion Therapeutics shares in Q2 2021, an estimated $28K.
Walleye Trading first reported a position in Cyclerion Therapeutics in Q1 2021 and held it in 1 quarter.
Walleye Trading's Cyclerion Therapeutics position peaked at $28K in Q1 2021.
67 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2021.

Based on Walleye Trading's 13F filing for Q2 2021, filed 16 Aug 2021.